455 related articles for article (PubMed ID: 22021518)
1. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
[TBL] [Abstract][Full Text] [Related]
2. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
3. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.
Naswa N; Sharma P; Nazar AH; Agarwal KK; Kumar R; Ammini AC; Malhotra A; Bal C
Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823
[TBL] [Abstract][Full Text] [Related]
5. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
10. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
11. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.
Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
[TBL] [Abstract][Full Text] [Related]
13. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
Ambrosini V; Castellucci P; Rubello D; Nanni C; Musto A; Allegri V; Montini GC; Mattioli S; Grassetto G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2009 Apr; 30(4):281-6. PubMed ID: 19247211
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of [
Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
[TBL] [Abstract][Full Text] [Related]
16. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns.
Krausz Y; Rubinstein R; Appelbaum L; Mishani E; Orevi M; Fraenkel M; Tshori S; Glaser B; Bocher M; Salmon A; Chisin R; Gross DJ; Freedman N
Clin Nucl Med; 2012 Jan; 37(1):57-62. PubMed ID: 22157030
[TBL] [Abstract][Full Text] [Related]
17. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).
Krausz Y; Freedman N; Rubinstein R; Lavie E; Orevi M; Tshori S; Salmon A; Glaser B; Chisin R; Mishani E; J Gross D
Mol Imaging Biol; 2011 Jun; 13(3):583-593. PubMed ID: 20652423
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
20. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
